3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
10
Gastrointestinal
5
Head & Neck
4
Dermatologic
4
Other solid neoplasm
3
Lymphoid
2
Genitourinary
2
Breast
2
Sarcoma
1
Gynecologic
1
Endocrine
1
Conditions
Lymphoma
725
Lymphoma, Non-Hodgkin
659
Precursor Cell Lymphoblastic Leukemia-Lymphoma
585
Leukemia, Lymphocytic, Chronic, B-Cell
555
Lymphoma, Large B-Cell, Diffuse
440
Lymphoma, Follicular
419
Lymphoma, Mantle-Cell
345
Burkitt Lymphoma
306
Leukemia
304
Leukemia, Myeloid, Acute
298
Hodgkin Disease
294
Lymphoma, B-Cell
281
Lymphoma, B-Cell, Marginal Zone
267
Recurrence
246
Multiple Myeloma
205
Neoplasms
200
Myelodysplastic Syndromes
171
Lymphoma, T-Cell, Cutaneous
171
Lymphoma, Large-Cell, Immunoblastic
160
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
159
Waldenstrom Macroglobulinemia
146
Lymphoma, Large-Cell, Anaplastic
142
Mycosis Fungoides
132
Sezary Syndrome
119
Immunoblastic Lymphadenopathy
108
Blast Crisis
92
Hematologic Neoplasms
91
Lymphoma, T-Cell, Peripheral
86
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
86
Lymphoma, T-Cell
82
Interventions
pembrolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Lymphoid
×
Clear all
NCT03010176
2025-10-29
MK-1454-001
Merck Sharp & Dohme LLC
Phase 1
Completed
156 enrolled
20 charts
NCT04317066
2025-04-06
KEYNOTE-A33
Merck Sharp & Dohme LLC
Phase 1
Completed
7 enrolled
13 charts